Investigation of the ABC Half-Transporter ABCG2

贵实验室长期以来对非pgp介导的耐药机制感兴趣，已经建立了几种以ABC半转运体ABCG2为重点的耐药细胞系模型。我们成功地从耐米托蒽醌结肠癌细胞系S1-M1-80中克隆了ABCG2，该细胞系表现出atp依赖性的药物积累减少。该基因包括6个跨膜结构域和一个ATP结合结构域，编码一个半转运蛋白分子，其活性需要二聚化。ABCG2的过度表达使细胞对米托蒽醌、喜树碱、拓扑替康和SN-38（伊立替康的活性代谢物）产生耐药性。ABCG2的底物和抑制剂的发现速度正在加快，并且各种底物和抑制剂都与p -糖蛋白相竞争。越来越多的证据支持ABCG2在限制药物的口服吸收和通过血脑屏障表达限制脑摄取方面的作用（见项目1）。我们研究了蛋白质的结构和功能关系。我们在ABCG2 （R482T; R482G）中发现了一种药物诱导的突变，它改变了底物和抑制剂的特异性。我们和其他人报道了在氨基酸141上携带单核苷酸多态性的细胞中运输受损，该多态性将谷氨酰胺转变为赖氨酸。由于拓扑替康的胃肠道吸收与肠上皮中ABCG2的表达有关，这项工作的一个含义是Q141K SNP可能与患者底物药物暴露增加有关。就ABCG2参与药物暴露的程度而言，该SNP可能增加对伊马替尼、伊立替康或拓扑替康等底物的暴露。此外，ABCG2在脑内皮细胞中表达，该蛋白的另一个重要作用是作为血脑屏障的组成部分保护中枢神经系统。这一发现的一个含义是，绕开ABCG2和血脑屏障的化合物可能在治疗或预防中枢神经系统转移方面具有更高的功效。随着我们在新药物如小分子酪氨酸激酶抑制剂中识别ABCG2底物，ABCG2在血脑屏障中定位的重要性将会增加。我们对ABCG2进行了广泛的结构和加工研究。我们研究了跨膜螺旋1中的gxxx二聚化基序；附近的残基T402完全破坏了蛋白质的稳定性；高度保守的氨基酸残基553（果蝇的同源残基被认为驱动二聚化）导致哺乳动物细胞表面蛋白质表达的丧失，氨基酸383中的关键残基可能促进蛋白质主要结构域之间的通信。最后，我们报道了表达高水平ABCG2的细胞在该基因的3'非翻译区被截断，从而去除一个microRNA结合位点。研究显示，microRNA hsa-miR 519c在该位点结合并减少基因表达和蛋白质翻译。新的研究表明，多种耐药细胞系使用短的3' UTR，这表明它是ABCG2上调的一般机制。我们研究了ABCG2的调控机制，发现在一些肾细胞癌细胞系中，ABCG2启动子甲基化，并且该启动子受组蛋白乙酰化的调控。罗米地辛能够上调某些细胞类型的表达。有趣的是，也有一些细胞类型的基因以非hdac、非甲基化依赖的方式被抑制。这项研究可能有助于我们了解正常干细胞在分化过程中如何关闭ABCG2，以及一些癌细胞如何重新表达转运蛋白；最终导致针对abcg2表达细胞的策略。我们还通过染色质免疫沉淀了解到，在对HDAC抑制有反应的细胞中，允许的表观遗传标记在ABCG2启动子中是明显的，ABCG2 mRNA上调。然而，在不响应HDAC抑制ABCG2 mRNA上调的细胞中，抑制表观遗传标记持续存在于ABCG2启动子中。尽管附近组蛋白赖氨酸尾部乙酰化，尽管同一细胞中其他基因上调，但这些抑制标记仍然存在于启动子中。这构成了研究对HDAC抑制剂耐药性的模型，这是项目#2:II的一个重要方面。组蛋白去乙酰化酶抑制剂抑郁肽的临床和实验室研究。在Michael Dean博士和James McMahon博士领导的分子靶标开发项目的合作下，ABCG2过表达细胞被用于筛选ABCG2抑制剂。这是一项重要的工作，因为无论ABCG2在肿瘤耐药中是否重要，其调节口服药物吸收和中枢神经系统摄取的潜在能力都将是重要的。分子靶标开发项目的柯蒂斯·亨里奇博士，已经确定了一些靶点，我们现在已经确认这些靶点是ABCG2抑制剂。这些化合物已经在我们的实验室和Suresh Ambudkar博士的实验室进行了二次筛选评估，以优先进行进一步的临床前开发。在另一种鉴定ABCG2底物和抑制剂的策略中，我们在NCI药物筛选的60个细胞系中表征了ABCG2的表达。该概况使我们能够使用COMPARE分析确定潜在的底物和抑制剂。这些化合物也进行了二次筛选。我们得出的结论是，药物筛选不能用于明确确定化合物是否为ABCG2底物，但是，通过这种方法可以富集一组化合物作为底物。我们的计划是与威廉·费格博士的团队合作，将这些化合物用于动物研究。特别是，我们希望评估这些抑制剂是否会增加CNS中ABCG2和Pgp药物底物的积累。临床研究也可能使用放射性标记显像剂（Pete Choyke博士和Jim Doroshow博士）与已用于临床试验的抑制剂联合使用。最后，我们已经确定了改善多态性ABCG2功能的策略，ABCG2是一种在氨基酸位置141处具有谷氨酰胺向赖氨酸转变的变体。这种变异首先与痛风易感性增加有关。在二聚化基序的基础上，我们通过添加底物研究了ABCG2的药理拯救作用。有趣的是，我们发现最好的抢救介质是罗咪地辛。这似乎是由于至少三个机制？增加了RNA表达，减少了向进攻性分子的转移，并且由于折叠的改善而改善了表面定位。这些研究的数据最近发表在《癌症研究》杂志上。总的来说，这项工作的最好特点是努力理解和利用ABCG2作为治疗靶点来改善抗癌治疗。

PROJECT SUMMARYOur laboratory has a long-standing interest in non-Pgp mediated mechanisms of drug resistance, having established several cell line models of resistance focusing on the ABC half-transporter ABCG2. We successfully cloned ABCG2 from a mitoxantrone-resistant colon cancer cell line, S1-M1-80, that exhibited an ATP-dependent reduction in drug accumulation. Comprising 6 transmembrane domains and a single ATP binding domain, the gene encodes a half-transporter molecule and dimerization is required for activity. Overexpression of ABCG2 renders cells resistant to mitoxantrone and to the camptothecins, topotecan and SN-38 (the active metabolite of irinotecan). Both substrates and inhibitors of ABCG2 have been discovered at an accelerating pace, and the variety of both substrates and inhibitors rivals that described for P-glycoprotein. Increasing evidence supports a role for ABCG2 in limiting the oral absorption of pharmacologic agents and in limiting the brain uptake through expression in the blood brain barrier (See project #1). We have worked on structure and function relationships in the protein. We identified a drug-induced mutation in ABCG2 (R482T; R482G) that alters substrate and inhibitor specificity. We and others reported impaired transport in cells bearing a single nucleotide polymorphism at amino acid 141 that changes glutamine to lysine. Since gastrointestinal absorption of topotecan has been related to ABCG2 expression in the intestinal epithelium, one implication of this work is that the Q141K SNP could be associated with increased exposure to substrate drugs in patients. To the extent that ABCG2 is involved in drug exposure, this SNP could increase exposure to substrates such as imatinib, irinotecan or topotecan. Further, ABCG2 is expressed in the endothelial cells in the brain and another important role for the protein is in protection of the CNS as a component of the blood-brain barrier. An implication of this finding is that compounds that circumvent ABCG2 and thus, the blood-brain barrier, could have increased efficacy in treating or preventing CNS metastases. The importance of localization of ABCG2 in the blood brain barrier will increase as we recognize ABCG2 substrates in new agents such as small molecule tyrosine kinase inhibitors.We have carried out extensive structure and processing studies in ABCG2. We studied a GXXXG dimerization motif in transmembrane helix 1; a nearby residue, T402, that completely destabilized the protein; the highly conserved amino acid residue 553 (the homologous residue in Drosophila is said to drive dimerization) that results in loss of protein expression on the mammalian cell surface, and a critical residue in amino acid 383 that may promote communication between the major domains of the protein. Finally we reported that cells expressing high levels of ABCG2 have truncation at the 3'untranslated region of the gene, which removes a microRNA binding site. The microRNA, hsa-miR 519c, was shown to bind at this site and reduce gene expression and protein translation. New studies have shown that a variety of drug resistant cell lines use the short 3' UTR, suggesting it as a general mechanism of ABCG2 upregulation.We studied mechanisms of regulation of ABCG2, discovering that the ABCG2 promoter is methylated in some renal cell cancer cell lines, and that the promoter is regulated by histone acetylation. Romidepsin is able to upregulate expression in some cell types. Interestingly, there are also cell types where the gene is repressed in a non-HDAC, non-methylation dependent manner. This study may help us understand how normal stem cells turn off ABCG2 as they differentiate and how some cancer cells re-express the transporter; eventually leading to strategies to target ABCG2-expressing cells. We have also learned using chromatin immunoprecipitation that permissive epigenetic marks are evident in the ABCG2 promoter in cells that respond to HDAC inhibition with upregulation of ABCG2 mRNA. However, repressive epigenetic marks persist in the ABCG2 promoter in cells that do not respond to HDAC inhibition with ABCG2 mRNA upregulation. These repressive marks persist in the promoter despite acetylation of the lysine tails of nearby histone proteins, and despite upregulation of other genes in the same cells. This constitutes a model for studying resistance to HDAC inhibitors, an important facet of project #2: II. Clinical and Laboratory Studies of the Histone Deacetylase Inhibitor Depsipeptide.In collaboration with Dr. Michael Dean and the Molecular Targets Development Program, led by Dr. James McMahon, ABCG2-overexpressing cells have been used to screen for inhibitors of ABCG2. This is an important undertaking since the potential ability to modulate oral drug absorption and CNS uptake will be important whether or not ABCG2 proves important in oncologic drug resistance. Dr. Curtis Henrich, of the Molecular Targets Development Program, has identified a number of hits that we have now confirmed as ABCG2 inhibitors. These compounds have been evaluated in secondary screens in our laboratory and in that of Dr. Suresh Ambudkar, to prioritize for further preclinical development. In another strategy to identify ABCG2 substrates and inhibitors, we characterized ABCG2 expression in the 60 cell lines of the NCI drug screen. This profile allowed us to identify potential substrates and inhibitors using the COMPARE analysis. These compounds have also been secondarily screened. We have concluded that the drug screen cannot be used to specifically define whether or not a compound is an ABCG2 substrate -- however, a set of compounds can be enriched for substrates by this method. Our plan is to take these compounds into animal studies in collaboration with Dr. William Figg's group. In particular, we hope to assess whether any of these inhibitors will increase CNS accumulation of ABCG2 and Pgp drug substrates. Clinical studies may also be possible using radiolabeled imaging agents (Dr. Pete Choyke and Dr. Jim Doroshow) in combination with inhibitors already available for clinical testing. Finally, we have worked to identify strategies to improve the function of the polymorphic ABCG2, a variant bearing a glutamine to lysine transition at amino acid position 141. This variant was first linked with an increased susceptibility to gout. Based on our work with the dimerization motif we have studied the pharmacologic rescue of ABCG2 through the addition of substrates. Interestingly we found that the best mediator of rescue was romidepsin. This appears to be due to at least three mechanisms ? increased RNA expression, reduced transfer to the aggressome, and improved surface localization due to improved folding. Data from these studies were recently published in Cancer Research.Collectively, this work is best characterized as an effort to both understand and exploit ABCG2 as a therapeutic target to improve anticancer therapy.